Cryospray ablation (CSA) in the palliative treatment of squamous cell carcinoma of the esophagus
© Cash et al; licensee BioMed Central Ltd. 2007
Received: 22 November 2006
Accepted: 16 March 2007
Published: 16 March 2007
Esophageal carcinoma is the ninth most prevalent cancer worldwide with squamous cell carcinoma (SCCA) and adenocarcinoma accounting for the vast majority of new cases (13,900 in 2003). Cure rates in the U.S. are less than 10%, similar to lung cancer. More than 50% of patients with esophageal carcinoma present with unresectable or metastatic disease, are not surgical candidates, or display disease progression despite the addition of neoadjuvant chemoradiotherapy to surgery. Need for improved palliation exits.
This case describes a 73-year-old African American male who presented with recurrent squamous cell carcinoma (SCCA) of the esophagus who has a achieved complete remission for 24 months via endoscopic cryospray ablation.
Endoscopic cryo spray ablation warrants further investigation as a palliative treatment modality for esophageal cancer. This is the first reported case in the medical literature.
Esophageal carcinoma is the ninth most prevalent cancer worldwide with squamous cell carcinoma (SCCA) and adenocarcinoma accounting for the vast majority of new cases (13,900 in 2003 in the USA) [1, 2]. Cure rates in the U.S. are less than 10%, similar to lung cancer . The definitive surgical therapy, esophagectomy, can provide 10–26%, 5-year, disease-free, all-stage survival rates [3, 4]. However, more than 50% of patients with esophageal carcinoma present with unresectable or metastatic disease and are not surgical candidates, or display disease progression despite the addition of neoadjuvant chemoradiotherapy to surgery [3–5].
Cryospray ablation (CSA) using liquid nitrogen sprayed through a low pressure device has recently been described to be effective and safe in the treatment of Barrett's esophagus including high-grade dysplasia [6–12]. This case report describes the first use of CSA in a patient with recurrent SCCA for palliative treatment that has resulted in complete remission for 2 years.
Despite ongoing research in esophageal cancer, the overall median survival following curative esophagectomy has been shown to be 34–38.6 months [13, 14] with a 7 month median survival following detection of recurrent esophageal cancer . Palliation therapies are needed for both survival prolongation and symptom relief. Current palliation approaches include feeding tubes, dilation, stents, radiation, chemotherapy and various ablative techniques, all of which have benefits and risks [4, 15].
The mechanism of action underlying the injury caused by CSA is unique for an ablative technique. CSA induces apoptosis and causes cryonecrosis at super-cold temperatures (-76°C to -158°C), which results in transient ischemia at the CSA site and can cause immune stimulation . Some precancerous lesions such as Barrett's epithelium and many cancers are resistant to apoptosis and therefore might be uniquely suited for treatment by CSA . Work in the swine has laid the foundations for the use of CSA. Initially, research was conducted to define the optimum cryogen dosimetry. This was followed by depth-of-injury work using endoscopic ultrasonography (EUS) and then comparative trials of CSA, MPEC and APC. Depth of injury at doses of 20 seconds times two cycles approximates 2 mm. Longer duration freezes achieve greater depths of injury .
It is unclear at this point what stages of esophageal cancer could potentially be treated/palliated with this modality. However, in this particular case and based on the degree of stricturing that followed it is likely that full esophageal wall thickness injury occurred. Thus palliation of tumors up to T4 (tumor invading adjacent structures) is conceivable.
The stricture that developed in this case was significant and required multiple interventions. Other potential complications of CSA include perforation, and bleeding. It is unknown what the actual complication rates are for this modality at this dose due to its relative novelty. In the first trial published by Johnston et al., no complications were reported. They used a dosimetry of 20 seconds times two for the first 10 patients. The CSA complication rate relative to other ablation techniques such as photodynamic therapy (PDT) is also unknown. However, for PDT the esophageal stricture rate is 30 to 50% depending on the number of treatments.
This particular malignancy may have been a very indolent one with slow growth as evidenced by the significant time interval between the first and second esophageal cancer presentation. It is also conceivable that only one CSA treatment was necessary for the palliation of this tumor in that "cure" is highly unlikely in such a case. One application of CSA may have avoided the subsequent stricture. However, this case still represents the first of its kind in the medical literature using this device and technique to achieve a sustained remission for SCCA of the esophagus. CSA has advantages relative to other palliative measures in that it is simple to use, can be performed with a standard diagnostic upper endoscope, is relatively inexpensive, and has a low rate of complications . There is no photosensitivity as in PDT and most patients after CSA can resume eating and a normal lifestyle the same day. Although treatment of this patient resulted in a post treatment stricture, he has no evidence of recurrent malignancy two years post treatment. A sustained remission of this nature in recurrent SCCA is unusual. Although speculative, this sustained remission could relate to the unique mechanisms of action of CSA. These mechanisms of injury include the induction of apoptosis, cryonecrosis, and systemic anti-tumor immune stimulation [18–20]. The effectiveness of CSA in the treatment of neoplasms such as prostate cancer can also be enhanced by certain chemotherapeutic agents such as 5-fluorouracil . These mechanisms of injury in concert with the method of delivery may make CSA an ideal option for the palliative treatment of esophageal neoplasms. Pilot studies indicate that mucosa damaged by cryotherapy followed by healing in an acid-free environment results in re-epithelialization with normal squamous epithelium in the majority of patients .
Some precancerous lesions such as Barrett's epithelium and many cancers are resistant to apoptosis and therefore might be uniquely suited for treatment by CSA. This case report describes the first use of CSA in a patient with recurrent SCCA for palliative treatment that has resulted in complete remission for 2 years. Further investigation using CSA as a palliative measure for esophageal cancer should be considered.
We would like to thank Jennifer Cartledge the engineer who co-invented this device with Dr. Johnston who has made innumerable refinements to make this device and technique a safe and very promising palliative modality for esophageal cancer.
We would like to thank Jacinda Foggy the CSA Medical technician who has helped with virtually all procedures performed and has helped manage much of the clinical data.
We would like to thank CSA Medical Inc. who supplied the cryospray ablation (CSA) device to the National Naval Medical Center under a Cooperative Research And Development Agreement (CRADA).
Since this was a single case Humanitarian Use Device Exemption Study no funding was sought by the investigators or the institution. The written permission was obtained from the patient for publication of this study, the study was approved by the Institutional review board and permission from US FDA was obtained.
- Sun W, Haller D: Oncology:VI Pancreatic, gastric and other gastrointestinal cancers. ACP Medicine. Edited by: Dale DC, Federman DD. 2004, WebMD Inc
- Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics, 2003. CA Cancer J Clin. 2003, 53: 5-26.View ArticlePubMed
- Koshy M, Esiashvilli N, Landry JC, Thomas CR, Matthews RH: Multiple management modalities in esophageal cancer: Epidemiology, presentation and progression, work-up, and surgical approaches. Oncologist. 2004, 9: 137-146. 10.1634/theoncologist.9-2-137.View ArticlePubMed
- Posner MC, Forastiere AA, Minsky BD: Cancer of the Esophagus. Cancer: Principles & Practice of Oncology. Edited by: Devita, Vt, Hellman, S, Rosenberg, SA. 2005, Lippincott Williams & Wilkins, 7
- Koshy M, Esiashvilli N, Landry JC, Thomas CR, Matthews RH: Multiple management modalities in esophageal cancer: Combined modality management approaches. Oncologist. 2004, 9: 147-159. 10.1634/theoncologist.9-2-147.View ArticlePubMed
- Johnston MH, Schoenfeld PS, Mysore J, Kita JA, Dubois A: Endoscopic cryotherapy: A new technique for tissue ablation in theesophagus [Abstract]. Am J Gastroenterol. 1997, 92: A44-
- Johnston M, Horwhat J, Dubois A, Schoenfeld PS: Endoscopic cryotherapy in the swine esophagus: A follow-up study [Abstract]. Gastrointest Endosc. 1999, 49: AB126-View Article
- Johnston MH, Schoenfeld P, Mysore JV, Dubois A: Endoscopic spray cryotherapy: a new technique for mucosal ablation in the esophagus. Gastrointest Endosc. 1999, 50: 86-92. 10.1016/S0016-5107(99)70352-4.View ArticlePubMed
- Johnston MH, Horwhat JD, Haluszka O, Moses FM: Depth of injury following spray cryotherapy: EUS assisted evaluation of mucosal ablation and subsequent healing in the swine model. [Abstract]. Gastrointest Endosc. 2000, 51: AB98-3462.View Article
- Johnston MH, Eastone JA, Horwhat JD: Reversal of barrett's esophagus with cryotherapy [Abstract]. Am J Gastroenterol. 2003, 98 (9 Suppl): A30,S11-
- Johnston MH: Cryotherapy and other newer techniques. Gastrointestinal Endosc. 2003, 13: 491-504. 10.1016/S1052-5157(03)00044-8.View Article
- Johnston MH, Eastone JA, Horwhat JD, Cartledge J, Mathews JS, Foggy JR: Cryoablation of Barrett's Esophagus: a pilot study. Gastrointest Endosc. 2005, 62: 842-848. 10.1016/j.gie.2005.05.008.View ArticlePubMed
- Hofstetter W, Swisher G, Correa AM, Hess K, Putnam JB, Ajani JA: Treatment outcomes of resected esophageal cancer. Ann Surg. 2002, 236: 376-385. 10.1097/00000658-200209000-00014.PubMed CentralView ArticlePubMed
- Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP: Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer. 2003, 97: 1616-1623. 10.1002/cncr.11228.View ArticlePubMed
- Lightdale CJ: Esophageal cancer. Am J Gastroenterol. 1999, 94: 20-29. 10.1111/j.1572-0241.1999.00767.x.View ArticlePubMed
- Grana L, Ablin RJ, Goldman S, Milhouse E: Freezing of the esophagus: Histological changes and immunological response. Int Surg. 1981, 66: 295-301.PubMed
- Dvorakova K, Payne CM, Ramsey L, Bernstein H, Holubec H, Chavarria M, Bernstein C, Sampliner RE, Riley C, Prasad A, Garewal H: Apoptosis resistance in Barrett's esophagus: ex vivo bioassy of live stressed tissue. Am J Gastroenterol. 2005, 100: 424-431. 10.1111/j.1572-0241.2005.40932.x.View ArticlePubMed
- Joosten JJA, Muijen GNP, Wobbes TH, Ruers TJM: In Vivo Destruction by Cryoablation Can Induce Inhibition of Secondary Tumor Growth: An Experimental Study. Cryobiology. 2001, 41: 49-58. 10.1006/cryo.2001.2302.View Article
- Hanai A, Yang W, Ravikumar TS: Induction of apoptosis in human colon carcinoma cells HT29 by sublethal cryo-injury: Mediation by cytochrome C release. Int J Cancer. 2001, 93: 526-533. 10.1002/ijc.1359.View ArticlePubMed
- Clarke DM, Baust JM, Buskirk RG, Baust JG: Chemo-Cryo Combination Therapy: An Adjunctive Model for the Treatment of Prostate Cancer. Cryobiology. 2001, 42: 274-285. 10.1006/cryo.2001.2333.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.